Science News
from research organizations

Novel criteria to differentiate fibrosis from steatohepatitis

March 5, 2010
World Journal of Gastroenterology
A research team from Germany and Switzerland identified serum transaminase levels below which a reliable cirrhosis assessment by FibroScan (FS) can be performed without interference of coexisting inflammation. Their study showed that postponing cirrhosis assessment by FS during alcohol withdrawal until glutamic oxaloacetic transaminase decreases to < 100 U/mL significantly improves the diagnostic accuracy.

Alcoholic liver disease (ALD) is the most common cause of liver cirrhosis in the Western world. Liver biopsy is currently considered the gold standard for assessing hepatic fibrosis or cirrhosis in these patients. However, it is an invasive procedure, with rare but potentially life-threatening complications and its accuracy is limited due to sampling error.

Transient elastography (FibroScan®, FS) is a novel rapid and noninvasive method to assess liver fibrosis via measurement of liver stiffness (LS). Although LS closely correlates with fibrosis stage, it also increases in patients with inflammation (steatohepatitis) which often confounds fibrosis in patients with ALD. Thus, novel criteria are urgently required to determine whether LS is increased due to fibrosis or inflammation.

A research article published on February 28, 2010 in the World Journal of Gastroenterology addresses this question. The research team lead by Dr. Sebastian Mueller from Heidelberg University identified in their recent study novel bedside criteria that allowed the differentiation of cirrhosis from inflammation in patients with ALD.

Their results showed that active inflammation of the liver (steatohepatitis) should be excluded first by blood tests prior to the noninvasive assessment of liver fibrosis by transient elastography. If glutamic oxaloacetic transaminase levels are < 100 U/L, the LS value can identify liver fibrosis and can be used as a diagnostic tool.

These novel criteria probably also hold true for other liver disease.

Story Source:

Materials provided by World Journal of Gastroenterology. Note: Content may be edited for style and length.

Journal Reference:

  1. Mueller S, Millonig G, Sarovska L, Friedrich S, Reimann FM, Pritsch M, Eisele S, Stickel F, Longerich T, Schirmacher P, Seitz HK. Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis. World Journal of Gastroenterology, 2010; 16 (8): 966 DOI: 10.3748/wjg.v16.i8.966

Cite This Page:

World Journal of Gastroenterology. "Novel criteria to differentiate fibrosis from steatohepatitis." ScienceDaily. ScienceDaily, 5 March 2010. <>.
World Journal of Gastroenterology. (2010, March 5). Novel criteria to differentiate fibrosis from steatohepatitis. ScienceDaily. Retrieved May 23, 2017 from
World Journal of Gastroenterology. "Novel criteria to differentiate fibrosis from steatohepatitis." ScienceDaily. (accessed May 23, 2017).